Primary hyperparathyroidism: molecular genetic insights and clinical implications

2017 ◽  
Author(s):  
Andrew Arnold
2012 ◽  
Vol 18 (3) ◽  
pp. 412-417 ◽  
Author(s):  
Leslie Eldeiry ◽  
Daniel Ruan ◽  
Edward Brown ◽  
Jason Gaglia ◽  
Jeffrey Garber

2011 ◽  
Vol 18 (9) ◽  
pp. 2555-2563 ◽  
Author(s):  
Giacomo Pata ◽  
Claudio Casella ◽  
Gian Carlo Magri ◽  
Silvia Lucchini ◽  
Maria Beatrice Panarotto ◽  
...  

2016 ◽  
Vol 88 (10) ◽  
pp. 57-62 ◽  
Author(s):  
E O Mamedova ◽  
N G Mokrysheva ◽  
E A Pigarova ◽  
E G Przhiyalkovskaya ◽  
I A Voronkova ◽  
...  

The article describes two clinical cases of severe primary hyperparathyroidism (PHPT) caused by parathyroid carcinoma in young female patients who underwent molecular genetic testing to rule out the hereditary forms of PHPT. In both patients, heterozygous germline nonsense mutations of tumor suppressor gene CDC73 encoding parafibromin (p.R91X and p.Q166X) were identified using next-generation sequencing with Ion Torrent Personal Genome Machine (Thermo Fisher Scientific — Life Technologies, USA). It is the first description of CDC73 mutations in Russia, one of the mutations is described for the first time in the world. Identification of germline mutations in the CDC73 gene in patients with PHPT necessitates regular lifelong screening for other manifestations of hyperparathyroidism-jaw tumor syndrome (HPT-JT), PHPT recurrence due to parathyroid carcinoma as well, and identification of mutation carriers among first-degree relatives.


2001 ◽  
Vol 10 (3) ◽  
pp. 213-226 ◽  
Author(s):  
J Niklinski ◽  
W Niklinska ◽  
L Chyczewski ◽  
HD Becker ◽  
E Pluygers

2009 ◽  
Vol 135 (4) ◽  
pp. 491-505 ◽  
Author(s):  
Sebastian Scholl ◽  
Hans-Joerg Fricke ◽  
Herbert G. Sayer ◽  
Klaus Höffken

2019 ◽  
Vol 26 (2) ◽  
pp. R53-R72 ◽  
Author(s):  
Kelly Brewer ◽  
Jessica Costa-Guda ◽  
Andrew Arnold

Primary hyperparathyroidism (PHPT) is a common endocrine disorder characterized by dysregulation of parathyroid hormone release. The large majority of PHPT cases are attributable to sporadic, single-gland parathyroid adenoma, in which MEN1 and CCND1/cyclin D1 are the most well-established drivers of tumorigenesis. Sporadic parathyroid carcinoma, which appears to mostly arise through molecular pathways distinct from those causing benign parathyroid tumors, is rare and is most frequently driven by mutational inactivation of the CDC73 (HRPT2) tumor suppressor gene. Targeted investigation of suspected tumor driver genes, as well as unbiased whole-genome or exome sequencing of small cohorts, have revealed additional novel candidate tumor genes in sporadic parathyroid neoplasia, generally at modest or low mutational frequencies consistent with marked molecular genetic heterogeneity from tumor to tumor. The ability of these additional candidates to participate in the pathogenic process of driving parathyroid tumorigenesis in vivo largely remains to be demonstrated experimentally. This review will summarize the molecular genetic abnormalities identified to date in sporadic PHPT and discuss the strength of evidence for their proposed roles in parathyroid tumor formation.


Sign in / Sign up

Export Citation Format

Share Document